Evidence and practice regarding the role for CY... [J Clin Oncol. 2010] - PubMed

loading

Review CYP2D6 and tamoxifen: DNA matters in breast cancer. [Nat Rev Cancer. 2009]
Review CYP2D6 and tamoxifen: DNA matters in breast cancer.
Hoskins JM, Carey LA, McLeod HL. Nat Rev Cancer. 2009 Aug; 9(8):576-86.
The ethics of CYP2D6 testing for patients considering tamoxifen. [Breast Cancer Res. 2007]
The ethics of CYP2D6 testing for patients considering tamoxifen.
Hartman AR, Helft P. Breast Cancer Res. 2007; 9(2):103.
Clinical significance of CYP2D6 polymorphisms and tamoxifen in women with breast cancer. [Clin Adv Hematol Oncol. 2008]
Clinical significance of CYP2D6 polymorphisms and tamoxifen in women with breast cancer.
Gaston C, Kolesar J. Clin Adv Hematol Oncol. 2008 Nov; 6(11):825-33.
The impact of CYP2D6-predicted phenotype on tamoxifen treatment outcome in patients with metastatic breast cancer. [Br J Cancer. 2010]
The impact of CYP2D6-predicted phenotype on tamoxifen treatment outcome in patients with metastatic breast cancer.
Lammers LA, Mathijssen RH, van Gelder T, Bijl MJ, de Graan AJ, Seynaeve C, van Fessem MA, Berns EM, Vulto AG, van Schaik RH. Br J Cancer. 2010 Sep 7; 103(6):765-71. Epub 2010 Aug 10.
Review Tamoxifen pharmacogenomics: the role of CYP2D6 as a predictor of drug response. [Clin Pharmacol Ther. 2008]
Review Tamoxifen pharmacogenomics: the role of CYP2D6 as a predictor of drug response.
Goetz MP, Kamal A, Ames MM. Clin Pharmacol Ther. 2008 Jan; 83(1):160-6. Epub 2007 Sep 19.

Tamoxifen metabolite concentrations, CYP2D6 genotype, and breast cancer outcomes. [Clin Pharmacol Ther. 2011]
Tamoxifen metabolite concentrations, CYP2D6 genotype, and breast cancer outcomes.
Madlensky L, Natarajan L, Tchu S, Pu M, Mortimer J, Flatt SW, Nikoloff DM, Hillman G, Fontecha MR, Lawrence HJ, et al. Clin Pharmacol Ther. 2011 May; 89(5):718-25. Epub 2011 Mar 23.
CYP2D6 inhibition and breast cancer recurrence in a population-based study in Denmark. [J Natl Cancer Inst. 2011]
CYP2D6 inhibition and breast cancer recurrence in a population-based study in Denmark.
Lash TL, Cronin-Fenton D, Ahern TP, Rosenberg CL, Lunetta KL, Silliman RA, Garne JP, Sørensen HT, Hellberg Y, Christensen M, et al. J Natl Cancer Inst. 2011 Mar 16; 103(6):489-500. Epub 2011 Feb 15.
Novel pathway analysis of genomic polymorphism-cancer risk interaction in the Breast Cancer Prevention Trial. [Int J Mol Epidemiol Genet. 2010]
Novel pathway analysis of genomic polymorphism-cancer risk interaction in the Breast Cancer Prevention Trial.
Dunn BK, Greene MH, Kelley JM, Costantino JP, Clifford RJ, Hu Y, Tang G, Kazerouni N, Rosenberg PS, Meerzaman DM, et al. Int J Mol Epidemiol Genet. 2010; 1(4):332-49. Epub 2010 Sep 5.

Related Citations
Calculated set of PubMed citations closely related to the selected article(s) retrieved using a word weight algorithm. Related articles are displayed in ranked order from most to least relevant, with the “linked from” citation displayed first.
Compound (MeSH Keyword)
PubChem chemical compound records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Substance (MeSH Keyword)
PubChem chemical substance (submitted) records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Cited in PMC
Full-text articles in the PubMed Central Database that cite the current articles.

Evidence and practice regarding the role for CYP2D6 inhibition in decisions abou...
Evidence and practice regarding the role for CYP2D6 inhibition in decisions about tamoxifen therapy.
J Clin Oncol. 2010 Mar 10 ;28(8):1273-5. Epub 2010 Feb 1 .

PubMed
Abnormalities of visual processing and frontostriatal systems in body dysmorphic...
Abnormalities of visual processing and frontostriatal systems in body dysmorphic disorder.
Arch Gen Psychiatry. 2010 Feb ;67(2):197-205.

PubMed
Hippocampal plasticity in response to exercise in schizophrenia.
Hippocampal plasticity in response to exercise in schizophrenia.
Arch Gen Psychiatry. 2010 Feb ;67(2):133-43.

PubMed
Cutting edge: priming of CD8 T cell immunity to herpes simplex virus type 1 requ...
Cutting edge: priming of CD8 T cell immunity to herpes simplex virus type 1 requires cognate TLR3 expression in vivo.
J Immunol. 2010 Mar 1 ;184(5):2243-6. Epub 2010 Feb 1 .

PubMed
International cohort analysis of the antiviral activities of zidovudine and teno...
International cohort analysis of the antiviral activities of zidovudine and tenofovir in the presence of the K65R mutation in reverse transcriptase.
Antimicrob Agents Chemother. 2010 Apr ;54(4):1520-5. Epub 2010 Feb 1 .

PubMed

Your browsing activity is empty.

Activity recording is turned off.

PubMed